Camurus AB (publ)

OM:CAMX Stock Report

Market Cap: SEK 32.2b

Camurus Valuation

Is CAMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CAMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CAMX (SEK548) is trading below our estimate of future cash flow value (SEK1344.04)

Significantly Below Future Cash Flow Value: CAMX is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAMX?

Key metric: As CAMX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CAMX. This is calculated by dividing CAMX's market cap by their current earnings.
What is CAMX's PE Ratio?
PE Ratio47.2x
EarningsSEK 682.13m
Market CapSEK 32.20b

Price to Earnings Ratio vs Peers

How does CAMX's PE Ratio compare to its peers?

The above table shows the PE ratio for CAMX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average81.4x
SECARE Swedencare
89.8x50.20%SEK 4.4b
ALIF B AddLife
34.5x14.93%SEK 19.6b
BIOA B BioArctic
123.1x53.32%SEK 26.8b
BONEX Bonesupport Holding
78.2x33.79%SEK 15.0b
CAMX Camurus
48x34.99%SEK 32.2b

Price-To-Earnings vs Peers: CAMX is good value based on its Price-To-Earnings Ratio (48x) compared to the peer average (80.9x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does CAMX's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CAMX 47.2xIndustry Avg. 21.2xNo. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CAMX is expensive based on its Price-To-Earnings Ratio (48x) compared to the European Pharmaceuticals industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is CAMX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAMX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio47.2x
Fair PE Ratio56.9x

Price-To-Earnings vs Fair Ratio: CAMX is good value based on its Price-To-Earnings Ratio (48x) compared to the estimated Fair Price-To-Earnings Ratio (56.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAMX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 539.00
SEK 771.38
+43.11%
10.84%SEK 914.00SEK 630.00n/a8
Jun ’27SEK 553.00
SEK 770.13
+39.26%
11.14%SEK 914.00SEK 620.00n/a8
May ’27SEK 531.00
SEK 770.13
+45.03%
11.80%SEK 930.00SEK 610.00n/a8
Apr ’27SEK 498.60
SEK 768.00
+54.03%
12.54%SEK 930.00SEK 610.00n/a7
Mar ’27SEK 503.00
SEK 768.00
+52.68%
12.54%SEK 930.00SEK 610.00n/a7
Feb ’27SEK 667.50
SEK 814.17
+21.97%
11.49%SEK 980.00SEK 660.00n/a6
Jan ’27SEK 616.00
SEK 793.71
+28.85%
11.56%SEK 980.00SEK 660.00n/a7
Dec ’26SEK 604.00
SEK 800.86
+32.59%
11.04%SEK 980.00SEK 660.00n/a7
Nov ’26SEK 624.50
SEK 823.83
+31.92%
16.55%SEK 1,116.00SEK 690.00n/a6
Oct ’26SEK 690.50
SEK 832.17
+20.52%
16.22%SEK 1,116.00SEK 690.00n/a6
Sep ’26SEK 718.00
SEK 832.17
+15.90%
16.22%SEK 1,116.00SEK 690.00n/a6
Aug ’26SEK 669.00
SEK 832.17
+24.39%
16.22%SEK 1,116.00SEK 690.00n/a6
Jul ’26SEK 607.00
SEK 786.14
+29.51%
18.97%SEK 1,116.00SEK 600.00n/a7
Jun ’26SEK 511.50
SEK 734.57
+43.61%
8.92%SEK 835.00SEK 600.00SEK 553.007
May ’26SEK 621.00
SEK 737.29
+18.73%
8.78%SEK 844.00SEK 610.00SEK 531.007
Apr ’26SEK 582.50
SEK 758.50
+30.21%
5.49%SEK 844.00SEK 715.00SEK 498.606
Mar ’26SEK 665.00
SEK 757.67
+13.93%
5.61%SEK 844.00SEK 710.00SEK 503.006
Feb ’26SEK 596.00
SEK 745.00
+25.00%
2.77%SEK 768.00SEK 710.00SEK 667.506
Jan ’26SEK 565.50
SEK 745.00
+31.74%
2.77%SEK 768.00SEK 710.00SEK 616.006
Dec ’25SEK 570.00
SEK 745.00
+30.70%
2.77%SEK 768.00SEK 710.00SEK 604.006
Nov ’25SEK 600.00
SEK 753.33
+25.56%
1.72%SEK 773.00SEK 730.00SEK 624.506
Oct ’25SEK 646.50
SEK 742.67
+14.87%
2.77%SEK 770.00SEK 710.00SEK 690.506
Sep ’25SEK 714.50
SEK 742.67
+3.94%
2.77%SEK 770.00SEK 710.00SEK 718.006
Aug ’25SEK 681.00
SEK 742.67
+9.06%
2.77%SEK 770.00SEK 710.00SEK 669.006
Jul ’25SEK 594.00
SEK 621.50
+4.63%
9.35%SEK 690.00SEK 500.00SEK 607.006
Jun ’25SEK 581.00
SEK 612.33
+5.39%
12.68%SEK 690.00SEK 445.00SEK 511.506
SEK 771.38
Fair Value
29.0% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 15:49
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Camurus AB (publ) is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Gonzalo Artiach CastanonDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie